HIV and AIDS: Medical Cannabis for Pain and Symptom Management

HIV-Associated Pain: A Persistent Challenge

• HIV-associated sensory neuropathy (HIV-SN) affects up to 50% of people living with HIV and is one of the most common causes of chronic pain in this population
• Antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition, but long-term ART itself can cause peripheral neuropathy
• Additional pain syndromes including headache, arthralgia, and abdominal pain are common in people living with HIV
• Standard analgesics including opioids are often poorly tolerated or interact with ART medications

Despite the success of modern antiretroviral therapy, chronic pain and associated symptoms remain a significant burden for many people living with HIV in the UK.

Evidence for Cannabis in HIV-Related Conditions

• Multiple RCTs conducted in the US and Canada have demonstrated that smoked and vaporised cannabis significantly reduce HIV-SN pain
• A landmark UCSF study showed that low doses of inhaled cannabis reduced neuropathic pain in HIV patients by over 30% compared to placebo
• Cannabis-induced appetite stimulation is particularly valuable in HIV patients with wasting syndrome or ART-related gastrointestinal side effects
• Dronabinol (synthetic THC) was licensed in the US specifically for HIV-related anorexia and weight loss, underscoring the therapeutic rationale

HIV-associated neuropathic pain is among the most extensively studied indications for medical cannabis, with robust trial data supporting its analgesic efficacy in this specific population.

UK Prescribing for People Living with HIV

• HIV specialists and sexual health physicians with relevant expertise can prescribe cannabis-based medicines under Schedule 2
• The British HIV Association has acknowledged the evidence base for cannabis in HIV-associated neuropathic pain in its treatment guidelines
• Immunological status must be considered before prescribing; patients with significant immunosuppression may face increased risk from vaporised flower
• CBD-dominant or oil-based formulations may be preferable for immunocompromised patients where the risks of inhaled cannabis are a concern

UK patients living with HIV who are experiencing chronic pain or other refractory symptoms should discuss cannabis as a therapeutic option with their HIV specialist or via a specialist prescribing clinic.

Interactions Between Cannabis and Antiretroviral Therapy

• CBD is a strong CYP3A4 inhibitor and may increase plasma levels of some protease inhibitors and integrase inhibitors
• ART medications including ritonavir can inhibit cannabis metabolism, increasing THC and CBD exposure unpredictably
• Pharmacokinetic interaction studies specific to cannabis and ART combinations are limited; clinical monitoring is essential
• The HIV specialist and cannabis prescriber must communicate closely to manage potential drug interactions and adjust doses accordingly

Drug interactions between cannabis and antiretroviral therapy require careful management, but they should not preclude cannabis prescribing for HIV patients; with appropriate monitoring they can be navigated safely.